Dr. Manuel Zevallos, MD

Dr. Zevallos practices at The Oncology Institute of Hope and Innovation - Lynwood in Lynwood, California.

Dr. Zevallos' NPI, 1174611750, was assigned on October 10, 2006. Dr. Zevallos graduated from National University of San Marcos in 1974. Dr. Zevallos holds California license A35871.

Dr. Zevallos' primary practice is The Oncology Institute of Hope and Innovation - Lynwood, at 3628 E Imperial Hwy, Lynwood, CA 90262 in Los Angeles County. The practice phone is (310) 945-8112.

Dr. Zevallos' primary practice is The Oncology Institute of Hope and Innovation - Lynwood in Lynwood, California. Dr. Zevallos is also affiliated with St. Francis Medical Center. The medical group on file is The Oncology Institute of Hope and Innovation. Dmand AI also links Dr. Zevallos to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Zevallos practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Zevallos' primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Zevallos is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Zevallos' licenses on file in 2 states: California and New Jersey.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, colorectal cancer, immune deficiency disease, lung cancer, lymphoma and neutropenia among the conditions Dr. Zevallos treats.

CMS data shows 656 Medicare services from Dr. Zevallos across 9 procedure codes in 2024, for 225 Medicare patients. Medicare paid $41,637 for them.

CMS counts 225 Medicare patients who saw Dr. Zevallos in 2024. The largest group is 65 to 74, with 109 patients. 75% of them have high blood pressure, and 70% have high cholesterol. 92% are also on Medicaid. Their average risk score is 2.42, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Zevallos' median patient age at 64, with 65% women.

In 2024, Dr. Zevallos wrote 1,012 Medicare Part D claims for 218 patients. 64% of them were for generic drugs. CMS names the drug for 627 of them, across 25 drugs with 11 or more claims each, at $2,394,154 in total drug cost. In 2023, CMS named 819 claims across 32 drugs.

Dr. Zevallos accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Zevallos as offering telehealth.

Dmand AI links 1 paper to Dr. Zevallos.

CMS Open Payments shows 1,601 general payments to Dr. Zevallos from 94 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 87% of the total. Janssen Pharmaceuticals, Inc paid the most, $3,735.

Dr. Zevallos graduated from National University of San Marcos in 1974.

Dr. Zevallos is in network with 13 carriers, including United Healthcare, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.